ATAI ATAI Life Sciences N.V.

Biotech Analyst Ratings

Latest News

1. 16 May 2022 atai Life Sciences Reports First Quarter 2022 Financial Results and Business Update

   – Strong execution across atai's three strategic pillars: rapid acting pharmacological intervention, ongoing digital support and biomarker-driven precision mental health
   

   – Key milestones include first subject dosed in Phase 1 KUR-101, launch of drug discovery engine Invyxis, initiation of Psyber usability study in patients and COMPASS' end of Phase 2 FDA meeting

   – Ended the first quarter with $335 million cash, maintaining atai's position as a well-funded, leading mental health company

   Video interview with Management to be posted today at 8:30 a.m. EDT

   NEW YORK and BERLIN, May 16, 2022 (GLOBE NEWSWIRE) -- atai Life Sciences N.V. (NASDAQ:ATAI) ("atai"), a clinical-stage biopharmaceutical company aiming to transform the treatment of mental…

   View Full Article
2. 10 May 2022 American Billionaire Entrepreneurs Bet Millions on Psychedelics

   FN Media Group Presents Microsmallcap.com Market Commentary

   NEW YORK, May 10, 2022 /PRNewswire/ -- Billionaire Bob Parsons, the founder of GoDaddy, believes psychedelics can heal trauma. The Marine infantryman says LSD and MDMA helped him alleviate symptoms related to PTSD, which he started suffering from after his Vietnam tour. Parsons and his wife have made several sizable donations in the space including $5 million to Mount Sinai's Psychedelic Research Center, and $2 million to the Multidisciplinary Association for Psychedelic Studies (MAPS), which will likely become the first company to win FDA approval for a therapy using MDMA to treat PTSD. Parsons isn't the only notable investor injecting money into the growing space. PayPal co-founder…

   View Full Article
3. 05 May 2022 CORRECTION - atai Life Sciences to Announce First Quarter 2022 Financial Results and Business Update

   NEW YORK, May 05, 2022 (GLOBE NEWSWIRE) -- In a release issued yesterday under the headline "atai Life Sciences to Announce First-Quarter 2022 Financial Results" by atai Life Sciences N.V. (NASDAQ:ATAI), please note the first and second paragraphs, which contained statements referencing the 2022 IR financial results posting and executives on the video interview, as well as forward-looking statements, have been modified. The corrected release follows:
   

   atai Life Sciences N.V. (NASDAQ:ATAI) ("atai"), a clinical-stage biopharmaceutical company aiming to transform the treatment of mental health disorders, plans to announce its first quarter 2022 financial results and business update on Monday, May 16, 2022.
   

   A video interview with atai management…

   View Full Article
4. 04 May 2022 atai Life Sciences to Announce First-Quarter 2022 Financial Results

   NEW YORK, May 04, 2022 (GLOBE NEWSWIRE) -- atai Life Sciences N.V. (NASDAQ:ATAI) ("atai"), a clinical-stage biopharmaceutical company aiming to transform the treatment of mental health disorders, will announce its first-quarter 2022 financial results by posting them on the IR portion of its website. Please visit the atai investor relations website at https://ir.atai.life to view Q1'22 financial results and press release.
   

   A video interview with atai Life Sciences CEO Florian Brand, CSO Srinivas Rao, and CFO Greg Weaver will be available at 8:30 A.M. Eastern Time at https://vimeo.com/atailifesciences. Questions that investors would like to see asked should be sent to [email protected] by Monday, May 9, 2022.

   About atai Life Sciences
   

   atai is a…

   View Full Article
5. 03 May 2022 Catalio Capital Management Raises $381 Million for Oversubscribed Third Life Sciences Fund

   Catalio's Flagship Strategy Will Continue to Identify and Invest in Breakthrough Biomedical Technology Companies Founded by Serial Scientist-Entrepreneurs

   Catalio Capital Management, LP ("Catalio"), a leading multi-strategy life sciences investment firm, today announced the successful close of its third venture fund, Catalio Nexus Fund III ("Fund III" or the "Fund"), with more than $381 million in total capital commitments, exceeding its original $300 million target. The Fund received significant backing from current Catalio investors and a number of new, global institutional investors, foundations and endowments.

   Launched in 2020 and led by Co-Founders George Petrocheilos and Dr. Jacob Vogelstein, Catalio manages more than $1 billion in…

   View Full Article